<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02705300</url>
  </required_header>
  <id_info>
    <org_study_id>FOLFOXIRI-Toco</org_study_id>
    <nct_id>NCT02705300</nct_id>
  </id_info>
  <brief_title>Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer</brief_title>
  <official_title>A Randomized Investigation of Side Effects to FOLFOXIRI in Combination With Tocotrienol or Placebo as First Line Treatment of Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment with FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) can be effective, but it
      has serious side effects, which may require hospitalization.

      The purpose of this study is to investigate whether the addition of tocotrienol can reduce
      the side effects to FOLFOXIRI otherwise leading to hospitalization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first serious adverse event</measure>
    <time_frame>6 months after the last patient has finished chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of non-planned hospitalizations calculated from date of first treatment until 1 month after completed chemotherapy</measure>
    <time_frame>6 months after the last patient has finished chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of non-planned hospitalizations calculated from date of first treatment until 1 month after completed chemotherapy</measure>
    <time_frame>6 months after the last patient has finished chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death during treatment calculated from date of first treatment until 1 month after completed chemotherapy</measure>
    <time_frame>6 months after the last patient has finished chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 months after the last patient has finished chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>6 months after the last patient has finished chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months after the last patient has finished chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment related adverse events as assessed by CTCAE v.4.0</measure>
    <time_frame>6 months after the last patient has finished chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by combined questionnaire consisting of EORTC QLQ-C30 and CR29</measure>
    <time_frame>6 months after the last patient has finished chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resection rate</measure>
    <time_frame>6 months after the last patient has finished chemotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy plus tocotrienol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 2 weeks: irinotecan 165 mg/m2 iv, oxaliplatin 85 mg/m2 iv, calcium folinate 200 mg/m2 iv, and 5-fluorouracil 3200 mg/m2 as a 46 hour infusion.
Daily: Tocotrienol 300 mg x 3 daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Every 2 weeks: irinotecan 165 mg/m2 iv, oxaliplatin 85 mg/m2 iv, calcium folinate 200 mg/m2 iv, and 5-fluorouracil 3200 mg/m2 as a 46 hour infusion.
Daily: Placebo x 3 daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan 165 mg/m2 iv</intervention_name>
    <description>Max. 4 months</description>
    <arm_group_label>Chemotherapy plus tocotrienol</arm_group_label>
    <arm_group_label>Chemotherapy plus placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin 85 mg/m2 iv</intervention_name>
    <description>Max. 4 months</description>
    <arm_group_label>Chemotherapy plus tocotrienol</arm_group_label>
    <arm_group_label>Chemotherapy plus placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium folinate 200 mg/m2 iv</intervention_name>
    <description>Max. 6 months</description>
    <arm_group_label>Chemotherapy plus tocotrienol</arm_group_label>
    <arm_group_label>Chemotherapy plus placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil 3200 mg/m2</intervention_name>
    <description>Max. 6 months</description>
    <arm_group_label>Chemotherapy plus tocotrienol</arm_group_label>
    <arm_group_label>Chemotherapy plus placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tocotrienol</intervention_name>
    <description>Max. 2 years or at the discretion of the investigator</description>
    <arm_group_label>Chemotherapy plus tocotrienol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Max. 2 years or at the discretion of the investigator</description>
    <arm_group_label>Chemotherapy plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically verified colorectal adenocarcinoma.

          -  Patients to receive first line treatment of metastatic disease, including potentially
             resectable or non-resectable disease

          -  &gt; 6 months without recurrence after end of adjuvant chemotherapy for radically treated
             stage II or III colorectal cancer

          -  Disease evaluable according to RECIST 1.1, but not necessarily measurable disease.

          -  Age 18-75 years

          -  Performance status (PS) 0-1. If age 71-75, then PS 0

          -  Life expectancy &gt; 3 months

          -  Organ and bone marrow function as follows:

               -  Neutrophil count ≥ 1.5 x 10^9/L

               -  Thrombocytes ≥ 100 x 10^9/L

               -  Total bilirubin ≤ 1.5 x upper level of normal (ULN)

               -  Alanine transaminase (ALAT) ≤ 2.5 x ULN (or≤ 5 x ULN in case of liver metastases)

          -  Fertile women must present negative pregnancy test. Male (with a female fertile
             partner) as well as female patients must use secure contraceptives during and 6 months
             after end of treatment.

          -  Orally and written informed consent to treatment and biobank

        Exclusion Criteria:

          -  Primarily resectable metastases

          -  Chemotherapy, radiotherapy or immunotherapy within 4 weeks

          -  Known neuropathy ≥ grade 2

          -  Serious competitive medical condition

          -  Other concurrent malignant disease other than non-melanoma skin cancer

          -  Previous serious and unexpected reactions to 5-fluorouracil, calcium folinate,
             oxaliplatin, irinotecan or capecitabine.

          -  Hypersensitivity to one or more of the active substances or auxilliary agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars H Jensen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, Vejle Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louise R Larsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, Vejle Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars H Jensen, PhD</last_name>
    <email>lars.henrik.jensen@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louise R Larsen, MD</last_name>
    <email>louise.raunkilde.larsen@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Oncology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars H Jensen, PhD</last_name>
      <email>lars.henrik.jensen@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Louise R Larsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2016</study_first_submitted>
  <study_first_submitted_qc>March 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2016</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

